2008). The GFP fusion proteins were affinity-purified on the beads and specifically associated proteins were analyzed by mass spectrometry. This procedure is commonly referred to as IP-MS in which the relative abundance of each interacting protein is reflected in their total spectrum counts of the resulting tryptic peptides (Fig. 1B and Tables S1-S2).
For transient transfection, HEK293 cells were seeded in 10 cm dishes at 2x10 6 cells per dish and transfected with a pEGFP-C2 derivative expressing GFP-ANKRA2 or a similar vector expressing GFP-RFXANK. Two days post-transfection, the cells were washed twice with PBS and lysed in situ with cold buffer B for preparation soluble extracts as described (Ullah et al., 2008) . For affinity purification, 25-30 µl GFP-TRAP beads were mixed with 1 ml soluble extracts prepared from one 10 cm plate of cells.
After washing four times with 0.5 ml buffer B per wash, bound proteins were eluted by incubation with 25-30 µl 50 mM H 3 PO4 (pH ~2.5) twice. The eluates were combined and used for immunoblotting and mass spectrometry.
For stable transfection, HEK293 cells were seeded in 12-well plates at 40,000 cells per well and transfected with pEGFP-C2 expressing GFP or a pEGFP-C2 derivative expressing GFP-ANKRA2. Two days post-transfection, the cells were washed once with PBS, trypsinized and transferred to 10 cm dishes for growing for 4 days in the presence of 0.8-1.0 mg/ml G418 (prepared in 0.1 M HEPES-NaOH pH7.2 and sterilized by filtration). Afterwards, the cells were washed with PBS and trypsinized. One tenth of the cell suspension was transferred onto a new dish for growth in the presence of 0.8-1.0 mg/ml G418. The remaining cell suspension was either discarded or frozen for storage at liquid nitrogen tank as the backup. After additional 4 days, the cells were washed and trypsinized for sorting GFP-positive cells on a FACS Aria sorter (BD Biosciences).
About 200,000 GFP-positive cells were used to grow up mixed stable clones expressing GFP or GFP-ANKRA2. For affinity purification, cells were grown in 10 cm dishes just prior to confluency. After washing twice with PBS, cells were lysed in situ with cold buffer B for preparation soluble extracts as described (Ullah et al., 2008) . The affinity purification was performed as described above.
Mass spectrometry
The general methods for sample preparation, including reduction, alkylation and tryptic digestion for mass spectrometry, have been described (Chen et al., 2009 ). We adapted a solid phase digestion workflow using SCX resin built inside silica tubing. The entire operation including sample loading, washing and elusion was propelled by pressurized air delivered from a nitrogen vessel. Briefly, silica tubing (200 µm, Polymicro Technology) was first sealed at one end by Kasil solution and then packed with ~3 cm long SCX resin.
The column was subsequently equilibrated with 10 mM KH 2 PO 4 pH 3.0. Samples of eluted immunoprecipitates were loaded onto column under 600 psi of air pressure. After washing with the KH 2 PO 4 buffer and H 2 O, samples were reduced in 2 µl 100 mM dithiothrietol for 30 min and then washed in 10 mM NH 4 HCO 3 pH 8.0. Proteins were digested on the column with trypsin in 100 mM Tris-HCl pH 8.0 and 10 mM iodoacetamide for 1 h at room temperature. The resulting peptides were eluted with 200 mM NH 4 HCO 3 and acidified with formic acid. The tryptic samples were analyzed on an LC-MS system consisting of a microflow liquid chromatography system (HP1100, Agilent, Palo Alto, CA) and a linear Ion Trap Mass Spectrometer (LTQ Orbitrap Velos, Thermo Finnigan, San Jose, CA). Peptides were separated by reverse-phase HPLC on a custom-packed PicoFrit Column (New Objective, Woburn, MA) during a run on a 90 min gradient. Buffer A was 5% acetonitrile and 0.1% formic acid, whereas buffer B was 90% acetonitrile and 0.1% formic acid. A flow rate of 350 nl/min was used for separation of the peptides. The column effluent was sprayed directly into the mass spectrometer.
Proteins were identified via query peptide sequences against the Ensembl database via the Mascot search algorithm (Matrix Science).
Bacterial protein expression and purification
Preparation of human ANKRA2 ankyrin repeats was performed as described (Xu et al., 2012) . Briefly, the coding sequence for human ANKRA2 ankyrin repeats (residues 142-313) was subcloned into pET28a-MHL vector. The vector was then transformed into E. coli BL21 (DE3) Codon plus RIL (Stratagene) and expressed as an N-terminal 6xHIS-tagged fusion protein. After induction by 1 mM IPTG at an OD600 of ~1.5, the recombinant protein was over-expressed at 18°C for extra 16-18 h. The recombinant protein was purified as described before (Xu et al., 2012) , on a Ni-NTA resin column (Qiagen) followed by gel filtration on a Superdex 75 column (GE Healthcare Life Sciences). Prior to gel filtration, the N-terminal 6xHis tag was removed by cleavage with TEV protease (Tobacco Etch Virus). All proteins were concentrated to 50 mg/ml in a buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 1 mM dithiothrietol, and stored at -80°C.
Cell-based ubiquitination assays
Rothbauer, U., Zolghadr, K., Muyldermans, S., Schepers, A., Cardoso, M.C., and Leonhardt, H. (2008) . A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteomics 7, 282--289. Ullah, M., Pelletier, N., Xiao, L., Zhao, S.P., Wang, K., Degerny, C., Tahmasebi, S., Cayrou, C., Doyon, Y., Goh, S.L., et al. (2008) . Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol 28, 6828--6843. Xu, C., Jin, J., Bian, C., Lam, R., Tian, R., Weist, R., You, L., Nie, J., Bochkarev, A., Tempel, W., et al. (2012) . Sequence--specific recognition of a PxLPxI/L motif by an ankyrin repeat tumbler lock. Sci Signal 5, ra39. (A) Domain organization of human RFX5 and RFX7 (NP_073752.5) with Drosophila RFX (CG9727, AAF54121). These three proteins display high sequence similarity within the RFX domain (green) located at the N-terminal regions. The Drosophila protein is more similar to RFX7 than to RFX5 in terms of the RFX domain and the potential 14-3-3 binding motifs. Also, the Drosophila genome does not appear to encode an RFXAP homolog, suggesting that the trimeric complex of RFX5, RFXANK and RFXAP was formed only later during evolution.
LEGENDS TO SUPPLEMENTAL FIGURES
(B) Sequence alignment of the RFX domains of Drosophila RFX and human RFX5. The key residues of the PxLPxL motif are shown in red, whereas the key M and P residues that make the PxLPxL motif of RFX5 prefer RFXANK over ANKRA2 are highlighted in green (Xu et al., 2012) . Note that the key M and P residue are not conserved in the fly homolog.
(C) Sequence comparison of the RFX domains of Drosophila RFX and human RFX7.
The key residues of the PxLPxL motif are shown in red, whereas the two residues corresponding to the M and P residues key to making the PxLPxL motif of RFX5 prefer RFXANK over ANKRA2 are highlighted in green (Xu et al., 2012) . Note that the key P residue is not conserved in RFX7, supporting that RFX7 prefers ANKRA2 over RFXANK (Figs 1C and 4) .
(D) Sequence comparison of the 14-3-3 motifs in Drosophila RFX and human RFX7.
Related to Fig. 1 . The three proteins linked to the 3M syndrome are highlighted in yellow. The red asterisk (*) denotes the existence of PxLPxL/I motif in a protein, and the green number sign ( # ) labels three proteins that form a trimeric complex playing an important role in bare lymphocyte syndrome. Related to Fig. 1 . 
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